| | | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | |
|---|
|
| August 2016 - 102 products |
|
| | | IP | CI | | Oxycodon-Naloxon-Mepha 5
mg/2.5 mg | 30 | 9.13 | 26.35 | 10 % | | Retard-Tabletten: 2 Active Agents | Mepha Pharma AG | A+ / SL / SG | FB | G |
| | | IP | CI | | Oxycodon-Naloxon-Mepha 5
mg/2.5 mg | 60 | 16.06 | 33.90 | 10 % | | Retard-Tabletten: 2 Active Agents | Mepha Pharma AG | A+ / SL / SG | FB | G |
| | | IP | CI | | Oxycodon-Naloxon-Mepha 10
mg/5 mg | 30 | 13.94 | 31.60 | 10 % | | Retard-Tabletten: 2 Active Agents | Mepha Pharma AG | A+ / SL / SG | FB | G |
| | | IP | CI | | Oxycodon-Naloxon-Mepha 10
mg/5 mg | 60 | 24.51 | 43.05 | 10 % | | Retard-Tabletten: 2 Active Agents | Mepha Pharma AG | A+ / SL / SG | FB | G |
| | | IP | CI | | Oxycodon-Naloxon-Mepha 20
mg/10 mg | 30 | 23.51 | 42.00 | 10 % | | Retard-Tabletten: 2 Active Agents | Mepha Pharma AG | A+ / SL / SG | FB | G |
| | | IP | CI | | Oxycodon-Naloxon-Mepha 20
mg/10 mg | 60 | 44.94 | 65.30 | 10 % | | Retard-Tabletten: 2 Active Agents | Mepha Pharma AG | A+ / SL / SG | FB | G |
| | | IP | CI | | Oxycodon-Naloxon-Mepha 40
mg/20 mg | 30 | 43.53 | 63.75 | 10 % | | Retard-Tabletten: 2 Active Agents | Mepha Pharma AG | A+ / SL / SG | FB | G |
| | | IP | CI | | Oxycodon-Naloxon-Mepha 40
mg/20 mg | 60 | 84.08 | 107.85 | 10 % | | Retard-Tabletten: 2 Active Agents | Mepha Pharma AG | A+ / SL / SG | FB | G |
| | | IP | CI | | Pramipexol ER Sandoz
0.375 mg | 10 | 4.53 | 14.15 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | G |
| | | IP | CI | | Pramipexol ER Sandoz 0.75 mg | 10 | 8.38 | 25.55 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | G |
| | | IP | CI | | Pramipexol ER Sandoz 0.75 mg | 30 | 23.39 | 41.85 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | G |
| | | IP | CI | | Pramipexol ER Sandoz 1.5 mg | 30 | 46.78 | 67.30 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum 1.5 mg | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | G |
| | | IP | CI | | Pramipexol ER Sandoz 3 mg | 30 | 93.57 | 118.20 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum 3 mg | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | G |
| | | IP | CI | | Pramipexol ER Sandoz 4.5 mg | 30 | 140.36 | 169.05 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum 4.5 mg | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | G |
| | | IP | CI | | Pramipexol-Mepha ER 0.375 mg | 10 | 4.53 | 14.15 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum | Mepha Pharma AG | B / SL / SG | FB | G |
| | | IP | CI | | Pramipexol-Mepha ER 0.75 mg | 10 | 8.38 | 25.55 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum | Mepha Pharma AG | B / SL / SG | FB | G |
| | | IP | CI | | Pramipexol-Mepha ER 0.75 mg | 30 | 23.39 | 41.85 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum | Mepha Pharma AG | ● B / SL / SG | FB | G |
| | | IP | CI | | Pramipexol-Mepha ER 1.5 mg | 30 | 46.78 | 67.30 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum 1.5 mg | Mepha Pharma AG | B / SL / SG | FB | G |
| | | IP | CI | | Pramipexol-Mepha ER 3 mg | 30 | 93.56 | 118.15 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum 3 mg | Mepha Pharma AG | B / SL / SG | FB | G |
| | | IP | CI | | Pramipexol-Mepha ER 4.5 mg | 30 | 140.34 | 169.05 | 10 % | | Retard-Tabletten: Pramipexoli Dihydrochloridum Monohydricum 4.5 mg | Mepha Pharma AG | B / SL / SG | FB | G |
| | | IP | CI | | Acarizax | 30 | 77.30 | 100.50 | 10 % | | | ALK-Abelló AG | A / SL | FB | G |
| | | IP | CI | | Acarizax | 90 | 231.92 | 268.65 | 10 % | | | ALK-Abelló AG | A / SL | FB | G |
| | | IP | | PP | Idelvion 250 IU | 250 IE | 529.27 | 584.05 | 10 % | | | CSL Behring Lengnau AG | B / SL | FB | G |
| | | IP | | PP | Idelvion 500 IU | 500 IE | 1058.53 | 1127.10 | 10 % | | | CSL Behring Lengnau AG | B / SL | FB | G |
| | | IP | | PP | Idelvion 1000 IU | 1000 IE | 2117.06 | 2213.15 | 10 % | | | CSL Behring Lengnau AG | B / SL | FB | G |
| | | IP | | PP | Idelvion 2000 IU | 2000 IE | 4234.12 | 4385.25 | 10 % | | | CSL Behring Lengnau AG | B / SL | FB | G |
| | | IP | CI | | Mezavant, 1,2 g
magensaftresistente
Retardtabletten | 60 | 47.32 | 67.90 | 10 % | | Mesalazinum 1.2 g | Takeda Pharma AG | B / SL | FB | G |
| | | IP | | PP | Idelvion 3500 IU | 3500 IE | 7409.71 | 7643.40 | 10 % | | Lyophilisat und Lösungsmittel: Albutrepenonacogum Alfa 3500 UI | CSL Behring Lengnau AG | B / SL | FB | G |
| | | IP | CI | | Adenuric 80 mg | 14 | 12.88 | 30.40 | 10 % | | Filmtabletten: Febuxostatum 80 mg | A. Menarini GmbH | B / SL | FB | G |
| | | IP | CI | | Adenuric 80 mg | 28 | 25.43 | 44.05 | 10 % | | Filmtabletten: Febuxostatum 80 mg | A. Menarini GmbH | B / SL | FB | G |
| | | IP | CI | | Adenuric 80 mg | 98 | 82.57 | 106.20 | 10 % | | Filmtabletten: Febuxostatum 80 mg | A. Menarini GmbH | B / SL | FB | G |
| | | IP | CI | PP | Uptravi 200 mcg | 60 | 4448.37 | 4854.30 | 10 % | | Filmtabletten: Selexipagum | Janssen-Cilag AG | B / SL | FB | G |
| | | IP | CI | PP | Uptravi 200 mcg | 140 | 9029.51 | 9572.10 | 10 % | | Filmtabletten: Selexipagum | Janssen-Cilag AG | B / SL | FB | G |
| | | IP | CI | PP | Uptravi 400 mcg | 60 | 4448.37 | 4854.30 | 10 % | | Filmtabletten: Selexipagum | Janssen-Cilag AG | B / SL | FB | G |
| | | IP | CI | PP | Uptravi 600 mcg | 60 | 4448.37 | 4854.30 | 10 % | | Filmtabletten: Selexipagum | Janssen-Cilag AG | B / SL | FB | G |
| | | IP | CI | PP | Uptravi 800 mcg | 60 | 4448.37 | 4854.30 | 10 % | | Filmtabletten: Selexipagum | Janssen-Cilag AG | B / SL | FB | G |
| | | IP | CI | PP | Uptravi 1000 mcg | 60 | 4448.37 | 4854.30 | 10 % | | Filmtabletten: Selexipagum 1 mg | Janssen-Cilag AG | B / SL | FB | G |
| | | IP | CI | PP | Uptravi 1200 mcg | 60 | 4448.37 | 4854.30 | 10 % | | Filmtabletten: Selexipagum 1.2 mg | Janssen-Cilag AG | B / SL | FB | G |
| | | IP | CI | PP | Uptravi 1400 mcg | 60 | 4448.37 | 4854.30 | 10 % | | Filmtabletten: Selexipagum 1.4 mg | Janssen-Cilag AG | B / SL | FB | G |
| | | IP | CI | PP | Uptravi 1600 mcg | 60 | 4448.37 | 4854.30 | 10 % | | Filmtabletten: Selexipagum 1.6 mg | Janssen-Cilag AG | B / SL | FB | G |
| | | IP | CI | | Nevanac 3 mg / ml | 3 ml | 12.73 | 30.25 | 10 % | | Augentropfensuspension: Nepafenacum 3 mg/ml | Novartis Pharma
Schweiz AG | B / SL | FB | G |
| | | IP | | | Kovaltry 500 I.E. | | 363.97 | 414.45 | 10 % | | Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung: Factor Viii Coagulationis Humanus 500 UI | Bayer (Schweiz) AG | B / SL | FB | G |
| | | IP | | | Kovaltry 1000 I.E. | | 727.49 | 787.45 | 10 % | | Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung: Factor Viii Coagulationis Humanus 1000 UI | Bayer (Schweiz) AG | B / SL | FB | G |
| | | IP | | | Kovaltry 2000 I.E. | | 1451.35 | 1530.15 | 10 % | | Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung: Factor Viii Coagulationis Humanus 2000 UI | Bayer (Schweiz) AG | B / SL | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | 12 | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | 12 | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | 12 | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 100 mg/ml | 12 | | | k.A. | | Injektionslösung: Asfotasum Alfa 100 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | | Xylo-Mepha Plus | 10 ml | | | k.A. | | Nasenspray: 2 Active Agents | Mepha Pharma AG | D | FB | G |
| | | IP | CI | PhCM | Traumalix dolo patch | 5 | | | k.A. | | Pflaster: Capsici Extractum Ethanolicum Liquidum 86.4 mg | Drossapharm AG | D | FB | G |
| | | IP | CI | PhCM | Traumalix dolo patch | 10 | | | k.A. | | Pflaster: Capsici Extractum Ethanolicum Liquidum 86.4 mg | Drossapharm AG | D | FB | G |
| | | | CI | | Selomida Haut | 30 x 7.5 g | | | k.A. | | Pulver zur Herstellung einer Lösung zum Einnehmen: 4 Active Agents | Schwabe Pharma AG | D | FB | G |
| | | | CI | | Selomida Muskeln | 30 x 7.5 g | | | k.A. | | Pulver zur Herstellung einer Lösung zum Einnehmen: 5 Active Agents | Schwabe Pharma AG | D | FB | G |
| | | | CI | | Selomida Verdauung | 30 x 7.5 g | | | k.A. | | Pulver zur Herstellung einer Lösung zum Einnehmen: 5 Active Agents | Schwabe Pharma AG | D | FB | G |
| | | | CI | H | Heidak Nervosität und
Überlastung | 30 ml | | | k.A. | | Spray zur Anwendung in der Mundhöhle: 6 Active Agents | Heidak AG | D | FB | G |
| | | | CI | H | Heidak Schlafstörungen | 30 ml | | | k.A. | | Spray zur Anwendung in der Mundhöhle: 6 Active Agents | Heidak AG | D | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | 12 | 10677.37 | 11262.80 | 10 % | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A / SL | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | 12 | 16609.24 | 17348.90 | 10 % | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A / SL | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | 12 | 23727.49 | 24652.20 | 10 % | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A / SL | FB | G |
| | | IP | CI | PP | Strensiq 100 mg/ml | 12 | 47454.97 | 48996.60 | 10 % | | Injektionslösung: Asfotasum Alfa 100 mg/ml | Alexion Pharma GmbH | A / SL | FB | G |
| | | IP | | | ChloraPrep coloré,
solution pour application
cutanée avec 3.0 ml
applicateur | 3 ml | | | k.A. | | 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep coloré,
solution pour application
cutanée avec 10.5 ml
applicateur | 10.5 ml | | | k.A. | | 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep coloré,
solution pour application
cutanée avec 26 ml
applicateur | 26 ml | | | k.A. | | 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep coloré,
solution pour application
cutanée avec 3.0 ml
applicateur | 25 x 3 ml | | | k.A. | | 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep coloré,
solution pour application
cutanée avec 10.5 ml
applicateur | 25 x 10.5 ml | | | k.A. | | 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | 12 | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 40 mg/ml | 12 | | | k.A. | | Injektionslösung: Asfotasum Alfa 40 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 100 mg/ml | | | | k.A. | | Injektionslösung: Asfotasum Alfa 100 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | PP | Strensiq 100 mg/ml | | | | k.A. | | Injektionslösung: Asfotasum Alfa 100 mg/ml | Alexion Pharma GmbH | A | FB | G |
| | | IP | CI | | Oxycodon-Naloxon-Mepha 30
mg/15 mg | 30 | | | k.A. | | Retard-Tabletten: 2 Active Agents | Mepha Pharma AG | A+ | FB | G |
| | | IP | CI | | Oxycodon-Naloxon-Mepha 30
mg/15 mg | 60 | | | k.A. | | Retard-Tabletten: 2 Active Agents | Mepha Pharma AG | A+ | FB | G |
| | | IP | CI | | Candesartan Stada 4 mg | 7 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 4 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 4 mg | 10 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 4 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 8 mg | 28 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 8 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 8 mg | 30 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 8 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 8 mg | 98 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 8 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 8 mg | 100 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 8 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 16 mg | 28 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 16 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 16 mg | 30 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 16 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 16 mg | 98 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 16 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 16 mg | 100 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 16 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 32 mg | 28 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 32 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 32 mg | 30 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 32 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 32 mg | 98 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 32 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | CI | | Candesartan Stada 32 mg | 100 | | | k.A. | | Tabletten: Candesartanum Cilexetilum 32 mg | Spirig HealthCare AG | B | FB | G |
| | | IP | | | ChloraPrep incolore | 1.5 ml | | | k.A. | | solution pour application cutanée avec applicateur: 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep incolore | 3 ml | | | k.A. | | solution pour application cutanée avec applicateur: 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep incolore | 10.5 ml | | | k.A. | | solution pour application cutanée avec applicateur: 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep incolore | 26 ml | | | k.A. | | solution pour application cutanée avec applicateur: 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep incolore | 20 x 1.5 ml | | | k.A. | | solution pour application cutanée avec applicateur: 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep incolore | 25 x 1.5 ml | | | k.A. | | solution pour application cutanée avec applicateur: 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep incolore | 60 x 1 ml | | | k.A. | | solution pour application cutanée avec applicateur: 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep incolore | 25 x 3 ml | | | k.A. | | solution pour application cutanée avec applicateur: 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
| | | IP | | | ChloraPrep incolore | 25 x 10.5 ml | | | k.A. | | solution pour application cutanée avec applicateur: 2 Active Agents | BD Switzerland Sàrl
Business Park Terre-
Bonne, Bâtiment A4 | D | FB | G |
